1.15
price up icon1.77%   0.02
after-market 시간 외 거래: 1.17 0.02 +1.74%
loading
전일 마감가:
$1.13
열려 있는:
$1.14
하루 거래량:
838.74K
Relative Volume:
0.45
시가총액:
$131.79M
수익:
$13.45M
순이익/손실:
$-178.23M
주가수익비율:
-0.697
EPS:
-1.65
순현금흐름:
$-132.53M
1주 성능:
+0.88%
1개월 성능:
-3.36%
6개월 성능:
-12.88%
1년 성능:
-73.07%
1일 변동 폭
Value
$1.125
$1.17
1주일 범위
Value
$1.10
$1.1897
52주 변동 폭
Value
$0.6611
$5.92

Fate Therapeutics Inc Stock (FATE) Company Profile

Name
명칭
Fate Therapeutics Inc
Name
전화
858.875.1803
Name
주소
12278 SCRIPPS SUMMIT DRIVE, SAN DIEGO, CA
Name
직원
181
Name
트위터
@fatethx
Name
다음 수익 날짜
2025-05-02
Name
최신 SEC 제출 서류
Name
FATE's Discussions on Twitter

FATE을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
FATE
Fate Therapeutics Inc
1.15 130.68M 13.45M -178.23M -132.53M -1.65
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
458.49 121.30B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
545.53 61.60B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
320.52 41.17B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
566.14 34.35B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.93 27.29B 3.81B -644.79M -669.77M -6.24

Fate Therapeutics Inc Stock (FATE) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2024-11-18 업그레이드 BofA Securities Underperform → Neutral
2024-06-17 업그레이드 Piper Sandler Neutral → Overweight
2023-03-27 재개 Wells Fargo Equal Weight
2023-01-24 다운그레이드 H.C. Wainwright Buy → Neutral
2023-01-06 다운그레이드 BMO Capital Markets Outperform → Market Perform
2023-01-06 다운그레이드 BofA Securities Buy → Underperform
2023-01-06 다운그레이드 Cowen Outperform → Market Perform
2023-01-06 다운그레이드 Piper Sandler Overweight → Neutral
2023-01-06 다운그레이드 Stifel Buy → Hold
2023-01-06 다운그레이드 Truist Buy → Hold
2023-01-06 다운그레이드 Wedbush Outperform → Neutral
2023-01-03 다운그레이드 Guggenheim Buy → Neutral
2022-12-22 다운그레이드 Oppenheimer Outperform → Perform
2022-12-15 개시 Goldman Sell
2022-11-04 재개 Cantor Fitzgerald Overweight
2022-10-10 개시 Canaccord Genuity Buy
2022-08-18 재개 Wells Fargo Overweight
2022-07-28 개시 Needham Hold
2022-07-11 업그레이드 BMO Capital Markets Market Perform → Outperform
2022-06-03 개시 Robert W. Baird Neutral
2022-02-11 재개 BMO Capital Markets Market Perform
2021-12-15 업그레이드 Wedbush Neutral → Outperform
2021-12-07 개시 Cowen Outperform
2021-11-09 업그레이드 Citigroup Neutral → Buy
2021-08-26 개시 Morgan Stanley Equal-Weight
2021-06-07 업그레이드 H.C. Wainwright Neutral → Buy
2021-05-07 업그레이드 Wedbush Neutral → Outperform
2021-04-26 재개 Jefferies Buy
2021-02-26 개시 BofA Securities Buy
2021-02-26 다운그레이드 Wedbush Outperform → Neutral
2021-02-11 다운그레이드 Citigroup Buy → Neutral
2021-01-27 재개 H.C. Wainwright Neutral
2020-05-13 개시 H.C. Wainwright Buy
2020-03-04 개시 Barclays Overweight
2020-01-09 다운그레이드 BMO Capital Markets Outperform → Market Perform
2019-12-30 재확인 Mizuho Buy
2019-12-09 업그레이드 Wells Fargo Market Perform → Outperform
2019-11-12 개시 SunTrust Buy
2019-11-06 다운그레이드 Wells Fargo Outperform → Market Perform
2019-10-01 개시 Stifel Buy
2019-08-09 개시 BTIG Research Buy
2019-07-22 개시 Cantor Fitzgerald Overweight
2019-07-12 개시 Oppenheimer Outperform
2019-06-13 개시 Mizuho Buy
2019-06-07 개시 ROTH Capital Neutral
2019-05-31 개시 Guggenheim Buy
2019-05-24 재개 Citigroup Buy
2019-03-28 개시 SVB Leerink Outperform
2019-01-03 다운그레이드 Stephens Overweight → Equal-Weight
2018-11-05 개시 Jefferies Buy
2018-08-01 개시 Citigroup Buy
2018-03-06 다운그레이드 H.C. Wainwright Buy → Neutral
모두보기

Fate Therapeutics Inc 주식(FATE)의 최신 뉴스

pulisher
Jul 21, 2025

What drives Fate Therapeutics Inc. stock priceUnstoppable trading performance - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Is Fate Therapeutics Inc. a good long term investmentFree Investment Portfolio Suggestions - Autocar Professional

Jul 21, 2025
pulisher
Jul 20, 2025

Fate Therapeutics Inc. Stock Analysis and ForecastFree Investment Community - jammulinksnews.com

Jul 20, 2025
pulisher
Jul 19, 2025

What analysts say about Fate Therapeutics Inc. stockUnbelievable profit margins - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 18, 2025

why fate therapeutics inc. stock attracts strong analyst attentionFree Day Trading Recommendations - Newser

Jul 18, 2025
pulisher
Jul 16, 2025

what makes fate therapeutics inc. stock price move sharplyIntraday Trade Ideas - Newser

Jul 16, 2025
pulisher
Jul 16, 2025

Fate Therapeutics, Inc. (FATE) Reaffirmed at Neutral After EULAR Data - MSN

Jul 16, 2025
pulisher
Jul 16, 2025

Fate Therapeutics, Inc. (NASDAQ:FATE) Receives Average Rating of “Hold” from Brokerages - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

How Fate Therapeutics Inc. stock performs during market volatilityMarket Beating Strategy - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Why Fate Therapeutics Inc. stock attracts strong analyst attentionFree Exclusive Investment Tips - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Fate Therapeutics Inc. stock price move sharplyFree Stock Selection - Newser

Jul 15, 2025
pulisher
Jul 14, 2025

We Think Fate Therapeutics (NASDAQ:FATE) Needs To Drive Business Growth Carefully - Yahoo Finance

Jul 14, 2025
pulisher
Jul 11, 2025

10 Best Get Rich Quick Stocks to Buy Now - Insider Monkey

Jul 11, 2025
pulisher
Jul 05, 2025

Research Analysts Offer Predictions for FATE Q2 Earnings - Defense World

Jul 05, 2025
pulisher
Jul 03, 2025

Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jul 03, 2025
pulisher
Jul 03, 2025

Fate Therapeutics shares rise 3.57% after-hours after granting non-qualified stock options to a new employee. - AInvest

Jul 03, 2025
pulisher
Jul 02, 2025

H.C. Wainwright maintains Neutral rating on Fate Therapeutics stock at $5 - Investing.com

Jul 02, 2025
pulisher
Jun 30, 2025

Fate Therapeutics, Inc.(NasdaqGM: FATE) added to Russell Microcap Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 28, 2025

Fate Therapeutics (NASDAQ:FATE) Downgraded to “Sell” Rating by Wall Street Zen - Defense World

Jun 28, 2025
pulisher
Jun 15, 2025

Institutional owners may take dramatic actions as Fate Therapeutics, Inc.'s (NASDAQ:FATE) recent 20% drop adds to one-year losses - simplywall.st

Jun 15, 2025
pulisher
Jun 14, 2025

Fate Therapeutics’ SWOT analysis: promising data boosts stock outlook - Investing.com

Jun 14, 2025
pulisher
Jun 14, 2025

TC Biopharm (NASDAQ:TCBP) versus Fate Therapeutics (NASDAQ:FATE) Critical Review - Defense World

Jun 14, 2025
pulisher
Jun 13, 2025

Fate Therapeutics (NASDAQ:FATE) Given “Hold” Rating at Needham & Company LLC - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

FATE: Analyst Maintains Hold Rating on Fate Therapeutics | FATE Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Needham maintains hold on Fate Therapeutics stock despite lupus data By Investing.com - Investing.com Canada

Jun 12, 2025
pulisher
Jun 12, 2025

Why Is Fate Therapeutics (FATE) Up 61.5% Since Last Earnings Report? - Yahoo Finance

Jun 12, 2025
pulisher
Jun 11, 2025

Fate Therapeutics price target lowered to $2.20 by BofA on SLE data - Investing.com Canada

Jun 11, 2025
pulisher
Jun 11, 2025

Fate Therapeutics (FATE) Shares Promising Data on FT819 for Lupus Treatment | FATE Stock News - GuruFocus

Jun 11, 2025
pulisher
Jun 11, 2025

Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress - The Manila Times

Jun 11, 2025
pulisher
Jun 11, 2025

Fate Therapeutics Reports Promising Clinical Data for FT819 in Treating Severe Lupus Nephritis at EULAR 2025 - Nasdaq

Jun 11, 2025
pulisher
Jun 11, 2025

Fate’s FT819 shows promising results in lupus patients - Investing.com

Jun 11, 2025
pulisher
Jun 11, 2025

Breakthrough: Fate's Off-the-Shelf CAR T-Cell Shows 100% Response Rate in Severe Lupus Patients - Stock Titan

Jun 11, 2025
pulisher
Jun 11, 2025

Squarepoint Ops LLC Purchases 20,805 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Bank of America Corp DE Sells 550,066 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 11, 2025
pulisher
Jun 11, 2025

Cantor Fitzgerald Comments on FATE FY2026 Earnings - Defense World

Jun 11, 2025
pulisher
Jun 10, 2025

Top Cancer Stocks to Supercharge Your 2025 Portfolio - Yahoo Finance

Jun 10, 2025
pulisher
Jun 10, 2025

Two Sigma Investments LP Cuts Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 10, 2025
pulisher
Jun 10, 2025

Jane Street Group LLC Has $51,000 Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 10, 2025
pulisher
Jun 08, 2025

Millennium Management LLC Increases Position in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 08, 2025
pulisher
Jun 06, 2025

Ameriprise Financial Inc. Sells 72,581 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 06, 2025
pulisher
Jun 06, 2025

Public Employees Retirement System of Ohio Sells 46,100 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Fate Therapeutics Inc (NASDAQ:FATE) Price Forecast For The Next 12 Months Is Set At 3. - Marketing Sentinel

Jun 05, 2025
pulisher
Jun 04, 2025

ProShare Advisors LLC Has $56,000 Stake in Fate Therapeutics, Inc. (NASDAQ:FATE) - Defense World

Jun 04, 2025

Fate Therapeutics Inc (FATE) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$21.69
price down icon 0.87%
$35.65
price up icon 0.17%
$102.78
price up icon 0.22%
$26.34
price up icon 0.53%
$108.91
price down icon 1.01%
biotechnology ONC
$291.93
price down icon 0.89%
자본화:     |  볼륨(24시간):